Floatz Rating
B60/100
Confidence
Indicative
Sponsor
University of Wisconsin, Madison
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03600350CT.gov pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02411786CT.gov A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF | — | Completed | — | — | — |
NCT01530984CT.gov Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | — | Withdrawn | — | — | — |
NCT01784913CT.gov A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer | — | Completed | — | — | — |
NCT02058680CT.gov Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients | — | Unknown | — | — | — |
NCT00814892CT.gov Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer | — | Terminated | — | — | — |
NCT00488982CT.gov Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC) | — | Completed | — | — | — |
NCT00274287CT.gov GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere | — | Completed | — | — | — |
NCT00027599CT.gov APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00005992CT.gov Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | — | Unknown | — | — | — |
Show 2 more trialsShow fewer
NCT00010127CT.gov Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer | — | Terminated | — | — | — |
NCT00678054CT.gov Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gm-Csf (this asset) | University of Wisconsin, Madison | P2 | B · 60 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Gm-Csf
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P4 | BBB · 74 |
| Melanoma | — | P4 | BBB · 74 |
| Uveal Melanoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gm-Csf in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gm-csf-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →